cenersen: antineoplastic p53 antisense oligonucleotide [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 168325608 |
| MeSH ID | M0571312 |
| Synonym |
|---|
| cenersen |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| thalidomide | phthalimides; piperidones | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| cytarabine | beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside | antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| vidarabine | beta-D-arabinoside; purine nucleoside | antineoplastic agent; bacterial metabolite; nucleoside antibiotic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| idarubicin | anthracycline antibiotic; deoxy hexoside; monosaccharide derivative | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | ||
| lenalidomide | aromatic amine; dicarboximide; isoindoles; piperidones | angiogenesis inhibitor; antineoplastic agent; immunomodulator | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| fludarabine | purine nucleoside | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| oligonucleotides | 2012 | 2013 | 11.8 | high | 1 | 0 | 0 | 0 | 5 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Myelogenous Leukemia | 0 | 2012 | 2012 | 12.0 | medium | 1 | 0 | 0 | 0 | 2 | 0 | |
| B-Cell Chronic Lymphocytic Leukemia | 0 | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 | |
| Dysmyelopoietic Syndromes | 0 | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Leukemia, Lymphocytic, Chronic, B-Cell | 0 | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 | |
| Leukemia, Myeloid, Acute | 0 | 2012 | 2012 | 12.0 | medium | 1 | 0 | 0 | 0 | 2 | 0 | |
| Myelodysplastic Syndromes | 0 | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Recrudescence | 0 | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Sensitivity and Specificity | 0 | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leukemia & lymphoma, , Volume: 53, Issue:2 | 2012 |